A meningococcal vaccine was supposed to prevent gonorrhea. In a trial, it didn't.

For nearly a decade, observational studies from several countries have pointed to the same intriguing signal: people vaccinated against meningococcal serogroup B disease seemed to get gonorrhea less often than people who weren't. The finding was plausible on biological grounds — the meningococcal vaccine 4CMenB and the bacterium that causes gonorrhea, Neisseria gonorrhoeae, are close enough relatives that cross-protection made mechanistic sense — and promising enough that a randomized trial to confirm it felt overdue, given decades without a dedicated gonorrhea vaccine and rising antibiotic resistance in the pathogen.

That trial has now reported its result, in the 8 July issue of the New England Journal of Medicine. It found no protective effect [s1].

What the trial tested

The study, known as GoGoVax, was a multicenter, double-blind, randomized, placebo-controlled trial that enrolled men who have sex with men at high risk for gonorrhea — specifically, participants who had recently been diagnosed with a gonorrhea infection or infectious syphilis, and who were either HIV-negative and taking pre-exposure prophylaxis or living with HIV [s1]. Participants were randomized 1:1 to receive two doses of 4CMenB or placebo, then followed with quarterly screening — nucleic acid testing at urogenital, anorectal and oropharyngeal sites — for two years [s1]. The primary outcome was time to a first gonorrhea infection in the group of participants who completed both doses and at least two follow-up visits [s1].

From July 2021 through May 2023, 654 people underwent randomization, and 587 were included in the primary efficacy analysis [s1].

What the trial found

The incidence of gonorrhea infection was 48.1 events per 100 person-years in the vaccinated group and 47.8 events per 100 person-years in the placebo group — an incidence rate ratio of 1.01, statistically indistinguishable from no effect, and a calculated vaccine efficacy of −0.5 percent [s1]. The confidence interval around that figure — −26.2 to 19.9 percent — is wide enough to rule out anything resembling the protective effect suggested by earlier observational data, while still being compatible with either a small benefit or a small harm that the trial was not sized to detect precisely.

Breaking the result down by infection type did not surface a hidden benefit. Vaccine efficacy was 5.5 percent for symptomatic infection, −6.4 percent for asymptomatic infection, and, by anatomical site, −20.0 percent for urogenital infection, −1.2 percent for anorectal infection, and 2.6 percent for oropharyngeal infection [s1] — a scatter of estimates straddling zero in both directions, consistent with random variation around no true effect rather than a real but modest benefit obscured by noise. Serious adverse events occurred in 4.7 percent of the 4CMenB group and 2.8 percent of the placebo group [s1]; the trial's published results do not characterize these events as vaccine-related.

Why this contradicts years of observational signal

The gap between what observational studies suggested and what this randomized trial found is worth sitting with, because it is a clean illustration of a recurring problem in vaccine and drug research: observational associations, however consistent across studies, can reflect confounding rather than causation. People who seek out meningococcal vaccination may differ systematically from those who don't — in healthcare-seeking behavior, sexual health screening frequency, or other factors that independently affect gonorrhea diagnosis rates — in ways that generate an apparent protective association without any biological effect of the vaccine at all.

That is precisely the scenario a randomized, placebo-controlled trial is designed to rule out, and in this case, it did. The trial's authors do not offer an alternative explanation for the discrepancy in the results as reported; the finding stands as a direct contradiction of the observational literature that motivated the study.

What this means, and what it doesn't

This result does not affect 4CMenB's established role in preventing meningococcal disease, which remains its approved and evidence-supported indication. What it does close, at least on the strength of this trial, is the specific hope that an already-available vaccine could double as gonorrhea prevention without a purpose-built product. For a pathogen with growing rates of antibiotic resistance and no dedicated vaccine, that would have been a meaningfully faster path to a preventive tool than starting gonorrhea vaccine development from scratch. This trial suggests that path does not work, at least at the dose and schedule tested here.

It leaves the underlying need — a vaccine against Neisseria gonorrhoeae itself — unaddressed. Other candidate approaches, including vaccines designed specifically against gonococcal antigens rather than repurposed meningococcal formulations, remain in earlier stages of development.

What to watch

Whether other 4CMenB dosing regimens or booster schedules are tested before the repurposing approach is abandoned entirely, and whether researchers revisit the observational studies that originally suggested protection to identify what confounding factors may have driven the earlier signal. This article describes trial results and is not guidance on gonorrhea prevention; screening and prevention decisions should be discussed with a healthcare provider.

Sources

• [s1] Seib KL, Donovan B, Jin F, et al., "Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection," New England Journal of Medicine, 8 July 2026. https://doi.org/10.1056/nejmoa2516739